17,261 trials
Renal Failure
Primary: Pharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation — 382.72; 147.82 ng*hr/mL
Atopic Dermatitis
Primary: Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD) — -2.30; -1.75 Scores on a scale — p=0.276
Depression · Depressive Disorder, Major
Primary: Change in Depression Severity — -5.4; -3.7 units on a scale — p=.003
Hepatitis C · Pharmacokinetics
Primary: Number of Participants With Investigator Defined Drug-related Adverse Events in Triple Combination Therapy — 3; 6; 6; 5 participants
Non-small Cell Lung Cancer
Primary: Response Rate — 32 Percentage of Participants
Acute Myelogenous Leukemia
Primary: Disease-free Survival at 6 Months — 0; 4 participants
Spinal Muscular Atrophy
Primary: Safety and Tolerability of Sodium Phenylbutyrate in Neonates and Infants With SMA — 1; 8; 0; 1 Participants
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Consolidation Progression-Free Survival — 13.3; 18.9 months
Lymphoma
Primary: Effect of Rituximab on EBV(+) Tumors — 0 relapses
Adult Angiosarcoma · Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma
Primary: Confirmed Response Rate (CR or PR) Using RECIST — 0 percentage of participants
Leukemia
Primary: Survival at Day 60 — 24 participants
Rheumatoid Arthritis
Primary: Part A: Average Difference Between Baseline and Post Dose Evoked (by Treadmill Walking) Lower-Extremity Pain Intensity Scores (AELEPID) Over the 6 Hours After Dosing…
Peripheral Neuropathy · Neuropathic Pain
Primary: Change From Baseline in Mean Numeric Pain Rating Scale (NPRS) Score — 1.02; 1.74; 1.51 units on a scale
Recurrent Clostridium Difficile Infection
Primary: Incidence of Serious Adverse Events Through 56 Days After the Last Treatment With RBX2660 — 10 number of reported SAEs through 56 days
Breast Cancer
Primary: Number of Patients With Decreased Gene Expression of CYP19 in Breast Cancer by Adding COX-2 Inhibitor to Exemestane — 0; 0 patients